Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Survival Analysis of A Chinese Randomized Crossover Study Comparing Erlotinib to Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations

NCT01131429 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT01131429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01131429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Survival Analysis of A Chinese Randomized Crossover Study Comparing Erlotinib to Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2010
Completion date
June 30, 2015
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small cell lung, drug therapy, genes, egfr, neoplasms, lung